Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Edris, Badreddin ^a   Fletcher, Jonathan A ^b   West, Robert B ^a   Van De Rijn, Matt ^a   Beck, Andrew H ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CANTHARIDIN; DEOXYGLUCOSE; DOXORUBICIN; GEFITINIB; METFORMIN; RAPAMYCIN; TIOGUANINE;

ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LEIOMYOSARCOMA; PHENOTYPE; PRIORITY JOURNAL;

EID: 84866070620     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/805614     Document Type: Article

References (21)

1. Evans H. L., Shipley J., Fletcher C. D. M., Unni K. K., Mertens F., Pathology and genetics of tumours of soft tissue and bone. World Health Organization Classification Of Tumours 2002 Lyon, France IARC Press 131 134
2. Beck A. H., Lee C. H., Witten D. M., Gleason B. C., Edris B., Espinosa I., Zhu S., Li R., Montgomery K. D., Marinelli R. J., Tibshirani R., Hastie T., Jablons D. M., Rubin B. P., Fletcher C. D., West R. B., Van De Rijn M., Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene 2010 29 6 845 854 2-s2.0-76849102318 10.1038/onc.2009.381
3. D'Angelo E., Prat J., Uterine sarcomas: a review. Gynecologic Oncology 2010 116 1 131 139 2-s2.0-70749135317 10.1016/j.ygyno.2009.09.023
4. Lamb J., Crawford E. D., Peck D., Modell J. W., Blat I. C., Wrobel M. J., Lerner J., Brunet J. P., Subramanian A., Ross K. N., Reich M., Hieronymus H., Wei G., Armstrong S. A., Haggarty S. J., Clemons P. A., Wei R., Carr S. A., Lander E. S., Golub T. R., The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006 313 5795 1929 1935 2-s2.0-33749335282 10.1126/science.1132939 (Pubitemid 44497995)
5. Lamb J., The connectivity map: a new tool for biomedical research. Nature Reviews Cancer 2007 7 1 54 60 2-s2.0-33845876254 10.1038/nrc2044 (Pubitemid 46020847)
6. De Preter K., De Brouwer S., Van Maerken T., Pattyn F., Schramm A., Eggert A., Vandesompele J., Speleman F., Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clinical Cancer Research 2009 15 11 3690 3696 2-s2.0-66649108018 10.1158/1078-0432.CCR-08-2699
7. Vilar E., Mukherjee B., Kuick R., Raskin L., Misek D. E., Taylor J. M. G., Giordano T. J., Hanash S. M., Fearon E. R., Rennert G., Gruber S. B., Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clinical Cancer Research 2009 15 8 2829 2839 2-s2.0-65249150218 10.1158/1078-0432.CCR-08-2432
8. Sirota M., Dudley J. T., Kim J., Discovery and preclinical validation of drug indications using compendia of public gene expression data. Science Translational Medicine 2011 3 102 102er7 10.1126/scitranslmed.3001318
9. Tusher V. G., Tibshirani R., Chu G., Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 2001 98 9 5116 5121 2-s2.0-0035942271 10.1073/pnas.091062498 (Pubitemid 32397092)
10. Rauh R., Kahl S., Boechzelt H., Bauer R., Kaina B., Efferth T., Molecular biology of cantharidin in cancer cells. Chinese Medicine 2007 2, article no. 8 2-s2.0-34547807709 10.1186/1749-8546-2-8
11. Efferth T., Rauh R., Kahl S., Tomicic M., Böchzelt H., Tome M. E., Briehl M. M., Bauer R., Kaina B., Molecular modes of action of cantharidin in tumor cells. Biochemical Pharmacology 2005 69 5 811 818 2-s2.0-13844267553 10.1016/j.bcp.2004.12.003 (Pubitemid 40248623)
12. Shan H.-B., Cai Y.-C., Liu Y., Zeng W.-N., Chen H.-X., Fan B.-T., Liu X.-H., Xu Z.-L., Wang B., Xian L.-J., Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A. Anti-Cancer Drugs 2006 17 8 905 911 2-s2.0-33748442867 10.1097/01.cad.0000217428.90325.35 (Pubitemid 44350609)
13. Lee D. H., Proteasome inhibitors: valuable new tools for cell biologists. Trends in Cell Biology 1998 8 10 397 403 2-s2.0-0032189348 10.1016/S0962- 8924(98)01346-4 (Pubitemid 28458705)
14. Lee Y. F., John M., Falconer A., A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Research 2004 64 article 7201 10.1158/0008-5472.CAN-04-1673 (Pubitemid 39372051)
15. Crawford L. J., Walker B., Irvine A. E., Proteasome inhibitors in cancer therapy. Journal of Cell Communication and Signaling 2011 5 2 101 110 10.1007/s12079-011-0121-7
16. Maki R. G., Kraft A. S., Scheu K., Yamada J., Wadler S., Antonescu C. R., Wright J. J., Schwartz G. K., A multicenter phase II study of bortezomib in ecurrent or metastatic sarcomas. Cancer 2005 103 7 1431 1438 2-s2.0-15744364211 10.1002/cncr.20968 (Pubitemid 40410740)
17. Rickardson L., Fryknäs M., Haglund C., Lövborg H., Nygren P., Gustafsson M. G., Isaksson A., Larsson R., Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemotherapy and Pharmacology 2006 58 6 749 758 2-s2.0-33748467107 10.1007/s00280-006-0216-7 (Pubitemid 44351254)
18. Zhang L., He M., Zhang Y., Nilubol N., Shen M., Kebebew E., Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing. Journal of Clinical Endocrinology and Metabolism 2012 97 3 E319 E328 2-s2.0-84858033697 10.1210/jc.2011-2671
19. Sherlock G., Hernandez-Boussard T., Kasarskis A., Binkley G., Matese J. C., Dwight S. S., Kaloper M., Weng S., Jin H., Ball C. A., Eisen M. B., Spellman P. T., Brown P. O., Botstein D., Cherry J. M., The stanford microarray database. Nucleic Acids Research 2001 29 1 152 155 2-s2.0-0035175010 10.1093/nar/29.1.152 (Pubitemid 32054432)
20. Mühlenberg T., Zhang Y., Wagner A. J., Grabellus F., Bradner J., Taeger G., Lang H., Taguchi T., Schuler M., Fletcher J. A., Bauer S., Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Research 2009 69 17 6941 6950 2-s2.0-70149091271 10.1158/0008-5472.CAN-08-4004
21. Edris B., Espinosa I., Mühlenberg T., ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. The Journal of Pathology 2012 227 2 223 233 10.1002/path.3986